FP
RPRX icon

Financial Perspectives’s Royalty Pharma RPRX Stock Holding History

Financial Perspectives’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Hold
2,155
– – 0.03% 225
2026
Q1 		$103K Hold
2,155
– – 0.03% 230
2025
Q4 		$83.3K Hold
2,155
– – 0.02% 252
2025
Q3 		$76K Hold
2,155
– – 0.02% 264
2025
Q2 		$77.6K Hold
2,155
– – 0.02% 256
2025
Q1 		$67.1K Hold
2,155
– – 0.02% 258
2024
Q4 		$55K Buy
+2,155
New +$57.1K 0.02% 284

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Perspectives's RPRX Position: Q2 2026 in Review

Financial Perspectives held its Royalty Pharma (RPRX) position steady in Q2 2026 at 2,155 shares worth $121K. The position accounts for 0.03% of the portfolio, ranked #225.

Financial Perspectives first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Financial Perspectives held 2,155 shares of Royalty Pharma worth $121K as of Q2 2026.
  • Financial Perspectives left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.03% of Financial Perspectives's portfolio in Q2 2026, its #225 holding.
  • Financial Perspectives first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.